Brain drug levels measured in healthy volunteers
NCT ID NCT02362516
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the drug Iclepertin (BI 425809) in 25 healthy men to see how much of it reaches the brain and how it affects certain brain chemicals. Participants took multiple doses of the tablet, and researchers measured drug levels in blood and spinal fluid. The main goals were to understand the drug's safety and how it behaves in the body, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 425809 (Iclepertin) tablet
What this could lead to
If successful, this could help determine the right dose for future studies of Iclepertin in conditions like Alzheimer's or schizophrenia.
What could go wrong
This is a very early Phase 1 study in only 25 healthy men, so it cannot prove the drug works for any disease. Side effects are possible but not yet well understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1346.3.32001 Boehringer Ingelheim Investigational Site
Antwerp, Belgium